1. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma
   Francesca Musumeci et al, 2021, Molecules CrossRef
2. PAK4 in cancer development: Emerging player and therapeutic opportunities
   Yixi Yuan et al, 2022, Cancer Letters CrossRef
3. The Combined Use of Orf Virus and PAK4 Inhibitor Exerts Anti-tumor Effect in Breast Cancer
   Hao Deng et al, 2022, Frontiers in Microbiology CrossRef
4. MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1
   Yan-Ling Chen et al, 2021, Oncology Letters CrossRef
5. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways
   Xinmei Liao et al, 2021, Frontiers in Oncology CrossRef
6. Combination of PAKs inhibitors IPA-3 and PF-3758309 effectively suppresses colon carcinoma cell growth by perturbing DNA damage response
   Muzaffer Dukel et al, 2023, International Journal of Radiation Biology CrossRef
7. Biological role of the PAK4 signaling pathway: A prospective therapeutic target for multivarious cancers
   Md. Mozibullah et al, 2023, Arabian Journal of Chemistry CrossRef
8. BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma
   Yan-Ling Chen et al, 2022, Cell & Bioscience CrossRef
9. The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment
   Yiling Wang et al, 2021, Cells CrossRef
10. p21-activated kinase 4 as a switch between caspase-8 apoptosis and NF-κB survival signals in response to TNF-α in hepatocarcinoma cells
    Qing Li et al, 2018, Biochemical and Biophysical Research Communications CrossRef
11. miR-135b-5p promotes gastric cancer progression by targeting CMTM3
    Mingdong Lu et al, 2017, International Journal of Oncology CrossRef
12. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
    Zhiheng Li et al, 2020, Frontiers in Oncology CrossRef
13. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
    Ann Lin et al, 2019, Science Translational Medicine CrossRef